Impact of wastewater treatment plants on receiving surface waters and a tentative risk evaluation: The case of estrogens and beta blockers

Environmental Science and Pollution Research

Volumn 21, Issue 3, 2014, Pages 1708-1722

  Gabet Giraud, V ^a   Miege C ^a   Jacquet, R ^a   Coquery, M ^a  

^a UR MALY   (France)

Author keywords

Beta blockers; Estrogens; Risk evaluation; Surface water; Wastewater treatment plant

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESTROGEN; ESTRONE;

ARTICLE; CHEMISTRY; ENVIRONMENTAL MONITORING; FRANCE; RISK ASSESSMENT; RIVER; SEWAGE; STATISTICS; WASTE WATER; WATER POLLUTANT;

ADRENERGIC BETA-ANTAGONISTS; ENVIRONMENTAL MONITORING; ESTROGENS; ESTRONE; FRANCE; RISK ASSESSMENT; RIVERS; SEWAGE; WASTE DISPOSAL, FLUID; WASTE WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84895073991     PISSN: 09441344     EISSN: 16147499     Source Type: Journal    
DOI: 10.1007/s11356-013-2037-7     Document Type: Article

References (59)

1. Andreozzi R, Raffaele M, Nicklas P (2003) Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere 50(10): 1319-1330.
2. Baronti C, Curini R, D'Ascenzo G, Di Corcia A, Gentili A, Samperi R (2000) Monitoring natural and synthetic estrogens at activated sludge sewage treatment plants and in a receiving river water. Environ Sci Technol 34(24): 5059-5066.
3. Belfroid AC, van der Horst A, Vethaak AD, Schafer AJ, Rijs GBJ, Wegener J, Cofino WP (1999) Analysis and occurrence of estrogenic hormones and their glucuronides in surface water and waste water in the Netherlands. Sci Total Environ 225(1-2): 101-108.
4. Bendz D, Paxeus NA, Ginn TR, Loge FJ (2005) Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Hoje River in Sweden. J Hazard Mater 122(3): 195-204.
5. Besse JP, Kausch-Barreto C, Garric J (2008) Exposure assessment of pharmaceuticals and their metabolites in the aquatic environment: application to the French situation and preliminary prioritization. Hum Ecol Risk Asses 14(4): 665-695.
6. Boyd GR, Reemtsma H, Grimm DA, Mitra S (2003) Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada. Sci Total Environ 311(1-3): 135-149.
7. Calamari D, Zuccato E, Castiglioni S, Bagnati R, Fanelli R (2003) Strategic survey of therapeutic drugs in the rivers Po and Lambro in northern Italy. Environ Sci Technol 37(7): 1241-1248.
8. Cargouet M, Perdiz D, Mouatassim-Souali A, Tamisier-Karolak S, Levi Y (2004) Assessment of river contamination by estrogenic compounds in Paris area (France). Sci Total Environ 324(1-3): 55-66.
9. Castiglioni S, Bagnati R, Fanelli R, Pomati F, Calamari D, Zuccato E (2006) Removal of pharmaceuticals in sewage treatment plants in Italy. Environ Sci Technol 40(1): 357-363.
10. Cleuvers M (2005) Initial risk assessment for three beta-blockers found in the aquatic environment. Chemosphere 59(2): 199-205.
11. Coetsier CM, Spinelli S, Lin L, Roig B, Touraud E (2009) Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs? Environ Int 35(5): 787-792.
12. European Commission, EU Commission Decision of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results (2002/657/EC), Offic. J. Eur. Commun. L221 (2002) 8.
13. Czajka CP, Londry KL (2006) Anaerobic biotransformation of estrogens. Sci Total Environ 367(2-3): 932-941.
14. Detroyer A, Heyden YV, Carda-Broch S, Garcia-Alvarez-Coque MC, Massart DL (2001) Quantitative structure-retention and retention-activity relationships of beta-blocking agents by micellar liquid chromatography. J Chromatogr A 912(2): 211-221.
15. European Commission JRC (2003) Technical guidance document in support of Commission Directive 93/67/EEC on Risk Assessment for new notified substances, Commission Regulation (EC) No 1488/94 on Risk Assessment for existing substances, Directives 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market, Part II Environmental Risk Assessment-Office for Official Publications of the European Communities, Luxembourg.
16. Farre M, Brix R, Kuster M, Rubio F, Goda Y, de Alda MJL, Barcelo D (2006) Evaluation of commercial immunoassays for the detection of estrogens in water by comparison with high-performance liquid chromatography tandem mass spectrometry HPLC-MS/MS (QqQ). Anal Bioanal Chem 385(6): 1001-1011.
17. Ferrari B, Mons R, Vollat B, Fraysse B, Paxeus N, Lo Giudice R, Pollio A, Garric J (2004) Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment? Environ Toxicol Chem 23(5): 1344-1354.
18. Gabet-Giraud V, Miege C, Choubert JM, Martin Ruel S, Coquery M (2010) Analysis of estrogens and beta blockers in the dissolved phase of wastewater treatment plants in France. Sci Total Environ 408: 4257-4269.
19. Garric J, Ferrari B, Fraysse B, Mons R, Vollat B (2006) Effects of some human pharmaceutical on freshwater organisms (Impact de médicaments à usage humain sur les organismes aquatiques d'eau douce). Environnement, Risques et Santé 5(4): 290-295.
20. Gros M, Petrovic M, Barcelo D (2006) Development of a multi-residue analytical methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for screening and trace level determination of pharmaceuticals in surface and wastewaters. Talanta 70(4): 678-690.
21. Grujic S, Vasiljevic T, Lausevic M (2009) Determination of multiple pharmaceutical classes in surface and ground waters by liquid chromatography-ion trap-tandem mass spectrometry. J Chromatogr A 1216(25): 4989-5000.
22. Gutjahr-Gobell RE, Zaroogian GE, Horowitz DJB, Gleason TR, Mills LJ (2006) Individual effects of estrogens on a marine fish, Cunner (Tautogolabrus adspersus), extrapolated to the population level. Ecotox Environ Safe 63(2): 244-252.
23. Haider S, Baqri SSR (2000) β-Adrenoceptor antagonists reinitiate meiotic maturation in Clarias batrachus oocytes. Comp Biochem Phys Mol Int Phys 126(4): 517-525.
24. Hansen PD, Dizer H, Hock B, Marx A, Sherry J, McMaster M, Blaise C (1998) Vitellogenin-a biomarker for endocrine disruptors. Trends Analyt Chem 17(7): 448-451.
25. Hernando MD, Gomez MJ, Aguera A, Fernandez-Alba AR (2007) LC-MS analysis of basic pharmaceuticals (beta-blockers and anti-ulcer agents) in wastewater and surface water. Trends Anal Chem 26(6): 581-594.
26. Huggett DB, Brooks BW, Peterson B, Foran CM, Schlenk D (2002) Toxicity of select beta adrenergic receptor-blocking pharmaceuticals (B-blockers) on aquatic organisms. Arch Environ Contam Toxicol 43(2): 229-235.
27. Huggett DB, Khan IA, Foran CM, Schlenk D (2003) Determination of beta-adrenergic receptor blocking pharmaceuticals in United States wastewater effluent. Environ Pollut 121(2): 199-205.
28. Isobe T, Shiraishi H, Yasuda M, Shinoda A, Suzuki H, Morita M (2003) Determination of estrogens and their conjugates in water using solid-phase extraction followed by liquid chromatography-tandem mass spectrometry. J Chromatogr A 984(2): 195-202.
29. Jobling S, Casey D, Rodgers-Gray T, Oehlmann J, Schulte-Oehlmann U, Pawlowski S, Baunbeck T, Turner AP, Tyler CR (2003) Comparative responses of molluscs and fish to environmental estrogens and an estrogenic effluent. Aquat Toxicol 65(2): 205-220.
30. Kasprzyk-Hordem B, Dinsdale RM, Guwy AJ (2007) Multi-residue method for the determination of basic/neutral pharmaceuticals and illicit drugs in surface water by solid-phase extraction and ultra performance liquid chromatography-positive electrospray ionisation tandem mass spectrometry. J Chromatogr A 1161(1-2): 132-145.
31. Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ (2009) The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters. Water Res 43(2): 363-380.
32. Kuch HM, Ballschmiter K (2001) Determination of endocrine-disrupting phenolic compounds and estrogens in surface and drinking water by HRGC-(NCI)-MS in the picogram per liter range. Environ Sci Technol 35(15): 3201-3206.
33. Kuster M, de Alda MJ, Hernando MD, Petrovic M, Martin-Alonso J, Barcelo D (2008) Analysis and occurrence of pharmaceuticals, estrogens, progestogens and polar pesticides in sewage treatment plant effluents, river water and drinking water in the Llobregat river basin (Barcelona, Spain). J Hydrol 358(1-2): 112-123.
34. Labadie P, Budzinski H (2005) Development of an analytical procedure for determination of selected estrogens and progestagens in water samples. Anal Bioanal Chem 381(6): 1199-1205.
35. Lagana A, Bacaloni A, De Leva I, Faberi A, Fago G, Marino A (2004) Analytical methodologies for determining the occurrence of endocrine disrupting chemicals in sewage treatment plants and natural waters. Anal Chim Acta 501(1): 79-88.
36. Larsson DGJ, Adolfsson-Erici M, Parkkonen J, Pettersson M, Berg AH, Olsson PE, Forlin L (1999) Ethinyloestradiol-an undesired fish contraceptive? Aquat Toxicol 45(2-3): 91-97.
37. Loos R, Wollgast J, Huber T, Hanke G (2007) Polar herbicides, pharmaceutical products, perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and nonylphenol and its carboxylates and ethoxylates in surface and tap waters around Lake Maggiore in Northern Italy. Anal Bioanal Chem 387(4): 1469-1478.
38. Loos R, Gawlik BM, Locoro G, Rimaviciute E, Contini S, Bidoglio G (2009) EU-wide survey of polar organic persistent pollutants in European river waters. Environ Pollut 157(2): 561-568.
39. Maurer M, Escher BI, Richle P, Schaffner C, Alder AC (2007) Elimination of beta-blockers in sewage treatment plants. Water Res 41(7): 1614-1622.
40. Miege C, Favier M, Brosse C, Canler JP, Coquery M (2006) Occurrence of betablockers in effluents of wastewater treatment plants from the Lyon area (France) and risk assessment for the downstream rivers. Talanta 70(4): 739-744.
41. Miege C, Bados P, Brosse C, Coquery M (2009a) Method validation for the analysis of estrogens (including conjugated compounds) in aqueous matrices. Trends Analyt Chem 28(2): 237-244.
42. Miege C, Choubert JM, Ribeiro L, Eusebe M, Coquery M (2009b) Fate of pharmaceuticals and personal care products in wastewater treatment plants-conception of a database and first results. Environ Pollut 157(5): 1721-1726.
43. Miege C, Karolak S, Gabet V, Jugan ML, Oziol L, Chevreuil M, Levi Y, Coquery M (2009c) Evaluation of estrogenic disrupting potency in aquatic environments and urban wastewaters by combining chemical and biological analysis. Trends Analyt Chem 28(2): 186-195.
44. Morteani G, Moller P, Fuganti A, Paces T (2006) Input and fate of anthropogenic estrogens and gadolinium in surface water and sewage plants in the hydrological basin of Prague (Czech Republic). Environ Geochem Heal 28(3): 257-264.
45. Nakada N, Tanishima T, Shinohara H, Kiri K, Takada H (2006) Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment. Water Res 40(17): 3297-3303.
46. Paffoni C, Welte B, Gousailles M, Montiel A (2006) New molecules involved by the European directives: from wastewater to drinking water treatment plants. Euro J Wat Qual 37(1): 21-38.
47. Peng XZ, Yu YJ, Tang CM, Tan JH, Huang QX, Wang ZD (2008) Occurrence of steroid estrogens, endocrine-disrupting phenols, and acid pharmaceutical residues in urban riverine water of the Pearl River Delta, South China. Sci Total Environ 397(1-3): 158-166.
48. Ren HY, Ji SL, Ahmad NUD, Dao W, Cui CW (2007) Degradation characteristics and metabolic pathway of 17 alpha-ethynylestradiol by Sphingobacterium sp JCR5. Chemosphere 66(2): 340-346.
49. Rodriguez-Mozaz S, de Alda MJL, Barcelo D (2004) Monitoring of estrogens, pesticides and bisphenol A in natural waters and drinking water treatment plants by solid-phase extraction-liquid chromatography-mass spectrometry. J Chromatogr A 1045(1-2): 85-92.
50. Stuer-Lauridsen F, Birkved M, Hansen LP, Lutzhoft HCH, Halling-Sorensen B (2000) Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere 40(7): 783-793.
51. Ternes TA (1998) Occurrence of drugs in German sewage treatment plants and rivers. Water Res 32(11): 3245-3260.
52. Ternes TA, Joss A (2006) Human pharmaceuticals, hormones and fragrances: the challenge of micropollutants in urban water management. IWA Publishing, London.
53. Ternes TA, Kreckel P, Mueller J (1999a) Behaviour and occurrence of estrogens in municipal sewage treatment plants-II. Aerobic batch experiments with activated sludge. Sci Total Environ 225(1-2): 91-99.
54. Ternes TA, Stumpf M, Mueller J, Haberer K, Wilken RD, Servos M (1999b) Behavior and occurrence of estrogens in municipal sewage treatment plants-I. Investigations in Germany, Canada and Brazil. Sci Total Environ 225(1-2): 81-90.
55. Vethaak AD, Lahr J, Schrap SM, Belfroid AC, Rijs GBJ, Gerritsen A, de Boer J, Bulder AS, Grinwis GCM, Kuiper RV, Legler J, Murk TAJ, Peijnenburg W, Verhaar HJM, de Voogt P (2005) An integrated assessment of estrogenic contamination and biological effects in the aquatic environment of the Netherlands. Chemosphere 59(4): 511-524.
56. Vieno NM, Tuhkanen T, Kronberg L (2006) Analysis of neutral and basic pharmaceuticals in sewage treatment plants and in recipient rivers using solid phase extraction and liquid chromatography-tandem mass spectrometry detection. J Chromatogr A 1134(1-2): 101-111.
57. Vigano L, Mandich A, Benfenati E, Bertolotti R, Bottero S, Porazzi E, Agradi E (2006) Investigating the estrogenic risk along the River Po and its intermediate section. Arch Environ Contam Toxicol 51(4): 641-651.
58. Vulliet E, Wiest L, Baudot R, Grenier-Loustalot MF (2008) Multi-residue analysis of steroids at sub-ng/L levels in surface and ground-waters using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr A 1210(1): 84-91.
59. Zhou JL, Zhang ZL, Banks E, Grover D, Jiang JQ (2009) Pharmaceutical residues in wastewater treatment works effluents and their impact on receiving river water. J Hazard Mater 166(2-3): 655-661.